Big Pharma-backed Atalanta Therapeutics is ramping up for the clinical debut of the company’s lead epilepsy asset in the wake of new data showing the RNA therapy ...

Investigators from Mass General Brigham and Beth Israel Deaconess Medical Center have developed STITCHR, a new gene editing tool that can insert therapeutic genes into specific locations without ...

Investigators from Mass General Brigham and Beth Israel Deaconess Medical Center have developed STITCHR, a new gene editing tool that can insert therapeutic genes into specific locations without ...

Durham-based Atsena Therapeutics has raised $150 million to advance gene therapies for preventing or reversing types of ...

Discover how an emerging technology called tRNA therapy could become the next big thing in genetic disease treatment.

New precision genome editing technologies are transforming the therapeutic landscape for patients with certain cancers and ...

A team of researchers led by Dr. Kim V. Narry, director of the Center for RNA Research at the Institute for Basic Science (IBS), has uncovered a key cellular mechanism that affects the function of ...

AIR-001 is designed to restore functional alpha-1 antitrypsin (M-AAT) protein production by precisely repairing the SERPINA1 mutation (PiZ) to address the underlying cause of both lung and liver ...

The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

RNA therapeutics market is expanding, driven by advancements in gene therapy, personalized medicine, and RNA-based drug delivery, along with rising research in mRNA vaccines, antisense ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

The versatile potential of RNA-LNP therapy also extends to the critical areas of women’s health. Specifically, RNA-LNP therapy presents two key applications in this field: (i) as a standalone or in ...